Cardio Diagnostics Holdings Inc., a leader in AI-powered precision cardiovascular medicine, has announced that it has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification letter from Nasdaq's Listing Qualifications Department confirming that its common stock's closing bid price traded above $1.00 per share from May 13 to May 27, 2025, following a 1:30 reverse stock split. This compliance ensures the continued listing of Cardio Diagnostics on The Nasdaq Capital Market, with Nasdaq considering the matter resolved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.